KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Retained Earnings (2016 - 2025)

Historic Retained Earnings for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to -$6.7 billion.

  • Alnylam Pharmaceuticals' Retained Earnings rose 803.02% to -$6.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.7 billion, marking a year-over-year increase of 803.02%. This contributed to the annual value of -$6.7 billion for FY2025, which is 803.02% up from last year.
  • As of Q4 2025, Alnylam Pharmaceuticals' Retained Earnings stood at -$6.7 billion, which was up 803.02% from -$7.2 billion recorded in Q3 2025.
  • Alnylam Pharmaceuticals' 5-year Retained Earnings high stood at -$4.8 billion for Q1 2021, and its period low was -$7.4 billion during Q2 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$6.8 billion (2023), whereas its average is -$6.5 billion.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 2282.21% in 2022, then soared by 803.02% in 2025.
  • Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Retained Earnings stood at -$5.4 billion in 2021, then fell by 20.8% to -$6.6 billion in 2022, then dropped by 6.7% to -$7.0 billion in 2023, then fell by 3.97% to -$7.3 billion in 2024, then grew by 8.03% to -$6.7 billion in 2025.
  • Its last three reported values are -$6.7 billion in Q4 2025, -$7.2 billion for Q3 2025, and -$7.4 billion during Q2 2025.